BACKGROUND: The reduced immunogenicity of the H5 hemagglutinin (HA), compared to seasonal HA serotypes, has stimulated searches for effective adjuvants to improve H5 vaccine efficacy. This study examined the immunogenicity and protective efficacy in ferrets immunized with a split-virion H5N1 vaccine combined with Advax™, a novel delta inulin-based polysaccharide adjuvant technology that has previously demonstrated ability to augment humoral and cellular immunity to co-administered antigens. METHODS: Ferrets were vaccinated twice 21 days apart with 7.5 μg or 22.5 μg of a split-virion preparation of A/Vietnam/1203/2004 with or without adjuvant. An additional group received just one immunization with 22.5 μg HA plus adjuvant. Serum antibodies were measured by hemagglutination inhibition and microneutralization assays. Vaccinated animals were challenged intranasally 21 days after the last immunization with 10(6) EID(50) of the homologous strain. Morbidity was assessed by observed behavior, weight loss, temperature, cytopenias, histopathology, and viral load. RESULTS: No serum neutralization antibody was detected after two immunizations with unadjuvanted vaccine. Two immunizations with high or low dose adjuvanted vaccine stimulated high neutralizing antibody titers. Survival was 100% in all groups receiving adjuvanted-vaccine including the single dose group, compared to 67% survival with unadjuvanted vaccine, and 0% survival in saline or adjuvant-alone controls. Minimal morbidity was seen in all animals receiving adjuvanted vaccine, and was limited to rhinorrhea and mild thrombocytopenia, without fever, weight loss, or reduced activity. H5N1 virus was cleared from the nasal wash by day 4 post-challenge only in animals receiving adjuvanted vaccine which also prevented viral invasion of the brain in most animals. CONCLUSIONS: In this initial study, Advax™ adjuvant formulations improved the protective efficacy of a split-virion H5N1 vaccine as measured by significantly enhanced immunogenicity, survival, and reduced morbidity.
BACKGROUND: The reduced immunogenicity of the H5 hemagglutinin (HA), compared to seasonal HA serotypes, has stimulated searches for effective adjuvants to improve H5 vaccine efficacy. This study examined the immunogenicity and protective efficacy in ferrets immunized with a split-virion H5N1 vaccine combined with Advax™, a novel delta inulin-based polysaccharide adjuvant technology that has previously demonstrated ability to augment humoral and cellular immunity to co-administered antigens. METHODS:Ferrets were vaccinated twice 21 days apart with 7.5 μg or 22.5 μg of a split-virion preparation of A/Vietnam/1203/2004 with or without adjuvant. An additional group received just one immunization with 22.5 μg HA plus adjuvant. Serum antibodies were measured by hemagglutination inhibition and microneutralization assays. Vaccinated animals were challenged intranasally 21 days after the last immunization with 10(6) EID(50) of the homologous strain. Morbidity was assessed by observed behavior, weight loss, temperature, cytopenias, histopathology, and viral load. RESULTS: No serum neutralization antibody was detected after two immunizations with unadjuvanted vaccine. Two immunizations with high or low dose adjuvanted vaccine stimulated high neutralizing antibody titers. Survival was 100% in all groups receiving adjuvanted-vaccine including the single dose group, compared to 67% survival with unadjuvanted vaccine, and 0% survival in saline or adjuvant-alone controls. Minimal morbidity was seen in all animals receiving adjuvanted vaccine, and was limited to rhinorrhea and mild thrombocytopenia, without fever, weight loss, or reduced activity. H5N1 virus was cleared from the nasal wash by day 4 post-challenge only in animals receiving adjuvanted vaccine which also prevented viral invasion of the brain in most animals. CONCLUSIONS: In this initial study, Advax™ adjuvant formulations improved the protective efficacy of a split-virion H5N1 vaccine as measured by significantly enhanced immunogenicity, survival, and reduced morbidity.
Authors: Erich Hoffmann; Aleksandr S Lipatov; Richard J Webby; Elena A Govorkova; Robert G Webster Journal: Proc Natl Acad Sci U S A Date: 2005-08-23 Impact factor: 11.205
Authors: T Rowe; R A Abernathy; J Hu-Primmer; W W Thompson; X Lu; W Lim; K Fukuda; N J Cox; J M Katz Journal: J Clin Microbiol Date: 1999-04 Impact factor: 5.948
Authors: Richard J Webby; Samita Andreansky; John Stambas; Jerold E Rehg; Robert G Webster; Peter C Doherty; Stephen J Turner Journal: Proc Natl Acad Sci U S A Date: 2003-05-29 Impact factor: 11.205
Authors: Robert Colby Layton; Andrew Gigliotti; Penny Armijo; Leslie Myers; Jennifer Knight; Nathaniel Donart; John Pyles; Sarah Vaughan; Jennifer Plourde; Ndingsa Fomukong; Kevin S Harrod; Peng Gao; Frederick Koster Journal: PLoS One Date: 2011-06-07 Impact factor: 3.240
Authors: Crina Stavaru; Adrian Onu; Emilia Lupulescu; Catalin Tucureanu; Orhan Rasid; Ene Vlase; Cristin Coman; Iuliana Caras; Alina Ghiorghisor; Laurentiu Berbecila; Vlad Tofan; Richard A Bowen; Nicole Marlenee; Airn Hartwig; Helle Bielefeldt-Ohmann; Susan L Baldwin; Neal Van Hoeven; Thomas S Vedvick; Chuong Huynh; Michael K O'Hara; Diana L Noah; Christopher B Fox Journal: Hum Vaccin Immunother Date: 2015-11-30 Impact factor: 3.452
Authors: Veena Menon; Victor I Ayala; Sneha P Rangaswamy; Irene Kalisz; Stephen Whitney; Lindsey Galmin; Asma Ashraf; Celia LaBranche; David Montefiori; Nikolai Petrovsky; Vaniambadi S Kalyanaraman; Ranajit Pal Journal: J Gen Virol Date: 2017-07-31 Impact factor: 3.891
Authors: Nikolai Petrovsky; Maximilian Larena; Venkatraman Siddharthan; Natalie A Prow; Roy A Hall; Mario Lobigs; John Morrey Journal: J Virol Date: 2013-07-17 Impact factor: 5.103